Sign up for e-mail alerts
|
Login
|
About PlusNews
|
Français
PlusNews
Global HIV/AIDS news and analysis
Advanced Search
GLOBAL
AFRICA
East Africa
Kenya
Sudan
Tanzania
Uganda
Great Lakes
Burundi
Central African Republic
Congo
DRC
Rwanda
Horn of Africa
Djibouti
Eritrea
Ethiopia
Somalia
Southern Africa
Angola
Botswana
Comoros
Lesotho
Madagascar
Malawi
Mauritius
Mozambique
Namibia
Seychelles
South Africa
Swaziland
Zambia
Zimbabwe
West Africa
Benin
Burkina Faso
Cameroon
Cape Verde
Chad
Cote d'Ivoire
Gabon
Gambia
Ghana
Equatorial Guinea
Guinea
Guinea-Bissau
Liberia
Mali
Mauritania
Niger
Nigeria
Sao Tome and Principe
Senegal
Sierra Leone
Togo
Western Sahara
ASIA
Afghanistan
Cambodia
Indonesia
Kyrgyzstan
Myanmar
Nepal
Pakistan
Papua New Guinea
Philippines
Sri Lanka
Thailand
Uzbekistan
MIDDLE EAST
Egypt
Iraq
Jordan
Lebanon
OPT
Yemen
AMERICAS
Haiti
26 July 2012
Home
Global Issues
In-Depth
Blog
Events
IRIN
Film
Weekly Reports
Countries
Afghanistan
Angola
Bangladesh
Benin
Botswana
Burkina Faso
Burundi
Cambodia
Cameroon
Cape Verde
Central African Republic (CAR)
Chad
Comoros
Republic of Congo
Cote d'lvoire
Djibouti
Democratic Republic of Congo (DRC)
Egypt
Equatorial Guinea
Eritrea
Ethiopia
Gabon
Gambia
Ghana
Guinea
Guinea-Bissau
Haiti
Indonesia
Iran
Iraq
Jordan
Kenya
Kyrgyzstan
Laos
Lebanon
Lesotho
Liberia
Madagascar
Malawi
Mali
Mauritania
Mauritius
Mozambique
Myanmar
Namibia
Nepal
Niger
Nigeria
occ. Palestinian terr.
Pakistan
Papua New Guinea
Philippines
Rwanda
Sao Tome and Principe
Senegal
Seychelles
Sierra Leone
Somalia
South Africa
Sri Lanka
Sudan
Swaziland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Turkmenistan
Uganda
Uzbekistan
Western Sahara
Yemen
Zambia
Zimbabwe
Themes
Aid Policy
Arts/Culture
Care/Treatment
Children
Conflict
Early Warning
Economy
Education
Environment
Food Security
Gender Issues
Governance
Health & Nutrition
HIV/AIDS
Media
Migration
Prevention
PWAs/ASOs
Stigma/Human Rights/Law
Urban Risk
Youth
Most read
In-depth: TB and HIV: Deadly allies
GLOBAL: Prevention the best medicine for TB
Photo: Manoocher Deghati/IRIN
Mineworkers in South Africa are highly vulnerable to TB
Johannesburg, 26 March 2009 (PlusNews) - Findings from an ongoing South African study into preventative tuberculosis (TB) therapy suggest that prevention really may be the best medicine.
In the Thibela TB study, one of the largest of its kind, almost 40,000 gold miners in South Africa received a nine-month course of isoniazid, a standard first-line TB drug. None of the miners was actually suffering from TB, but the high prevalence of both HIV and silicosis in South African mines makes miners extremely vulnerable to the disease.
Isoniazid preventive therapy (IPT) is usually given to people living with HIV to reduce their risk of developing TB, but the Thibela study is testing the theory that treating an entire community with the drug could have a significant impact on TB rates for a period of about 10 years.
The study, which is being conducted in three of the country’s nine provinces, is only expected to conclude in 2012, but preliminary findings released on Wednesday suggest that isoniazid has already been effective in reducing TB incidence among participants.
“We’ve had very few subsequent infections in those taking the preventative treatment,” said Dr Dave Clark, deputy CEO of the Aurum Institute, the health research NGO conducting the study.
The results could also influence case management of HIV-positive people in South Africa, who are around 20 times more likely to develop TB than those who are HIV-negative – 75 percent of new TB patients are HIV-positive.
The World Health Organization (WHO) has recommended IPT for people living with HIV in countries with a high prevalence of TB, but less than one percent of HIV-positive people in South Africa are receiving it, according to Clark.
Although many feared the preventative treatment would increase the incidence of drug-resistant TB, the number of such cases in the study has been negligible. Most patients also showed a surprising wiliness to adhere to treatment.
“Asking mineworkers, who are ostensibly well, to adhere to treatment is difficult,” Clark said. “We’ve had an 80 percent success rate to date with adherence, and it’s caught on. We’ve had cases where workers have asked, ‘Is this something we can take back to our communities, to our wives?’”
Findings from the study might also influence the way health workers and policy-makers handle epidemics other than TB. “If this methodology can work in this setting, there is huge potential that the approach would work in the case of other diseases, such as diabetes and hypertension,” said Clark.
In the latest global TB control report released by WHO on Tuesday, South Africa’s incidence of TB ranks second only to Swaziland’s, the highest in the world. South Africa also has the world's fourth highest burden of multidrug-resistant (MDR) TB.
llg/ks/he
TB and HIV: Deadly allies
March 2009
PDF file
Download this in-depth report
1 MB
PlusNews reports
GLOBAL: TB and HIV co-infection crisis a bigger threat
GLOBAL: Fatal ‘extensively-resistant’ tuberculosis spreads
GLOBAL: Prevention the best medicine for TB
KENYA: Corruption, erratic drug supply threatens TB treatment
LESOTHO-SOUTH AFRICA: Cross-border health crisis hits mineworkers
SOMALIA: TB treatment success against the odds in Somaliland
SOUTH AFRICA: Reducing TB a matter of life and death
SOUTH AFRICA: Saving more lives faster
SWAZILAND: The burden of drug-resistant TB
SWAZILAND: "It's TB that's killing people"
UGANDA: Low awareness hinders TB diagnosis and treatment
ZIMBABWE: Health crisis whacks TB efforts
In-Depth Feedback
PlusNews welcomes feedback. Send your messages to feedback.
Other OCHA Sites
Donors